Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022 08:30 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 16:05 ET
|
Satsuma Pharmaceuticals
- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of...
Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences
October 28, 2021 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
October 12, 2021 16:15 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
September 28, 2021 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
August 10, 2021 16:05 ET
|
Satsuma Pharmaceuticals
- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- - $121.2 million in cash as of June 30, 2021, provides runway into second half of 2023- SOUTH SAN...
Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
July 28, 2021 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals to Present at SVB Leerink’s CNS Forum
June 22, 2021 16:01 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
June 16, 2021 16:05 ET
|
Satsuma Pharmaceuticals
- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT Phase 3...